Research programme: small cell lung cancer therapeutics - DISCO Pharmaceuticals
Latest Information Update: 18 Jan 2024
At a glance
- Originator DISCO Pharmaceuticals
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Small cell lung cancer